anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To provide a means for vaccinating a neonatal human and animal against foreign antigens and antigens associated with diseases of human and animal, respectively.  <P>SOLUTION: In a method for using a virus for producing a medicament for vaccinating or treating the neonatal or prenatal animal, including the human, the virus has potency to infect the cells of the neonatal or prenatal animal, including the human, but has no potency to be replicated to an infectious progeny virus in the neonatal or prenatal animal, including the human. The virus is preferably a modified vaccinia virus Ankara. Particularly, the vaccination of neonates against infection with viruses belonging to the same virus group as the virus used for vaccination is provided. The vaccination of neonates against antigens selected from foreign antigens and tumor antigens different from antigens associated with the aforesaid virus is also provided. Furthermore, the use of the virus as defined above to increase the level of factors activating dendritic cells or their precursor cells and/or to increase the number of dendritic cells or their precursor cells and/or to increase the production amount and/or cellular content of an interferon (IFN) or IL-12 is provided.  <P>COPYRIGHT: (C)2010,JPO&INPIT
Nailfold capillary density is lower in patients with pulmonary arterial hypertension (PAH). It is unclear whether this observation signifies a unique systemic manifestation of PAH, or reflects microcirculatory dysfunction secondary to pulmonary hypertension (PH). Capillary density and loop dimensions were measured by nailfold-capillaroscopy (NC) in 30 PAH (23 idiopathic, or iPAH, 7 hereditary, or hPAH), 17 chronic thromboembolic PH (CTEPH) patients and 48 controls. NC-Measurements were repeated after pulmonary endarterectomy (PEA) or balloon pulmonary angioplasty (BPA) in CTEPH patients. We examined whether NC-measurements were related to markers of disease severity and predictive of time to clinical worsening (TTCW) as tested by univariate linear/logistic regression and cox-regression analysis, respectively. Capillary density was significantly lower in PAH (7.5 ± 1.1, p < 0.001) and in CTEPH (8.4 ± 1.5, p < 0.001) compared to asymptomatic controls (10.3 ± 1.0 capillaries/mm). Capillary density was similar in iPAH and hPAH and unrelated to hemodynamics in either PAH or CTEPH. A lower capillary density was predictive of clinical worsening in PAH (p 0.05). After normalization of pulmonary artery pressures by PEA or BPA, capillary density remained reduced in CTEPH patients. Capillary loop apex, capillary and venous- and arterial limb diameter were increased in patients with PAH and CTEPH compared to controls. Nailfold capillary density is reduced to a similar extent in iPAH, hPAH and CTEPH. Normalization of hemodynamics by PEA or BPA does not lead to a restoration of capillary density in CTEPH. Capillary dimensions were increased in both patients with PAH and CTEPH. Lower capillary density was predictive of clinical worsening in PAH. Our findings indicate that a loss of peripheral capillaries is not specific to PAH and is not related to the hemodynamic disturbance per se, but that shared mechanisms may account for a simultaneous development of a systemic microangiopathy and pulmonary vascular remodeling.
PURPOSE:An antithrombotic agent, containing a cyclohexanecarboxamide derivative as an active constituent, and having pharmacological actions, e.g. inhibitory action on blood platelet agglutination or cholesterol reducing action, with low toxicity. CONSTITUTION:An antithrombotic agent containing a cyclohexanecarboxamide derivative of formulaI(A is 1-4C lower alkyl, 1-4C lower alkoxyl, phenyl having 1-3 halogen, e.g. Cl, Br, F or I, nitro, hydroxyl groups, carboxyl or lower alkoxycarbonyl groups optionally substituted and pyridyl; R is alkyl; R<1> is H or methyl) as an active constituent. The unit dosage form is an oral agent, e.g. a tablet or capsule, or a parenteral agent, e.g. an injection or suppository. The content of the active constituent in the unit dosage form is preferably in the range of 25-2,000mg, and the active constituent is prepared from a compound of formula II and a compound of formula III.
OBJECTIVE: To evaluate the effectiveness of Eutectic Mixture of Local Anesthetic (EMLA), a topical anesthetic cream, in office-based invasive andrological procedures such as hydrocelectomy, spermatocelectomy, and others, aimed at minimizing pain perception and enhancing the overall patient experience.
METHODS: A double-blinded randomized controlled trial was conducted for patients undergoing scrotal andrology surgeries under LA. Power calculation was performed with an estimated sample size of 72. Participants were randomly assigned in a 1:1 ratio to topical EMLA + LA versus LA alone. In the post-operative recovery area, patient will be asked to complete a VAS questionnaire rating pain with LA administration and pain with procedure. Analysis comparing VAS pain scores of both groups was performed using the independent sample t-test method.
RESULTS: Seventy-two patients were included in our analysis, with 36 in the control and 36 in the intervention arm. For patient pain with administration of LA, the control arm reported an average VAS pain score of 4.31, compared to 3.72 in the intervention arm (P = .319). For patient pain with procedure, patients in the control arm reported a median VAS pain score of 3.47 compared to 3.03 (P = .432) in the intervention arm. Overall, 86% (62/72) of patients reported that they would either be "very likely" (4/5) or "highly likely" (5/5) to undergo future procedures under local anesthetic.
CONCLUSION: While performing scrotal surgeries under LA appears to be well tolerated and a feasible option, the application of EMLA cream does not appear to significantly alter patient-reported outcomes.
PURPOSE:To obtain the titled monomer having one or more double bonds in the molecule, by hydrolyzing a fluorine-contained multiple telomer containing vinyl acetate, having specific molecular weight, esterifying the hydrolyzate with (meth) acrylic acid chloride. CONSTITUTION:Vinyl acetate and two or more fluorine-contained compound (e.g., vinylidene fluoride, vinyl fluoride, etc.; preferably >=50wt% vinylidene fluoride) are subjected to telomerization using a lower alcohol, halogenated methane, halogenated ethane, lower ketone, etc. as a telogen, to give a telomer having <=1,500mol.wt. The telomer is hydrolyzed with an acid or alkali, and esterified with (meth)acrylic acid chloride, to give the desired compound. USE:An artificial denture base, weather-resistant paint, etc.
With the rapid development of smart grids, society has become increasingly urgent to solve the problems of low energy utilization efficiency and high energy consumption. In this context, load identification has become a key element in formulating scientific and effective energy consumption plans and reducing unnecessary energy waste. However, traditional load identification methods mainly focus on known electrical equipment, and accurate identification of unknown electrical equipment still faces significant challenges. A new encoding feature space based on Triplet neural networks is proposed in this paper to detect unknown electrical appliances using convex hull coincidence degree. Additionally, transfer learning is introduced for the rapid updating of the pre-classification model's self-incrementing class with the unknown load. In experiments, the effectiveness of our method is successfully tested on the PLAID dataset. The accuracy of unknown load identification reached 99.23%. Through this research, we expect to bring a new idea to the field of load identification to meet the urgent need for the identification of unknown electrical appliances in the development of smart grids.
Methods are provided for the synthesis of polymer conjugates of cytokines and receptor-binding antagonists thereof, especially a non glycosylated interferon-beta, which conjugates retain unusually high biological potency. Preparation of polymer conjugates according to the methods of the present invention diminishes or avoids steric inhibition of receptor-ligand interactions that commonly results from the attachment of polymers to receptor-binding regions of cytokines, as well as to agonistic and antagonistic analogs thereof. The invention also provides conjugates and compositions produced by such methods. The conjugates of the present invention retain a high level of biological potency compared to those produced by traditional polymer coupling methods that are not targeted to avoid receptor-binding domains of cytokines. In assays in vitro, the biological potency of the conjugates of non-glycosylated interferon-beta of the present invention is substantially higher than that of unconjugated interferon- beta and is similar to that of interferon-beta-1a that is glycosylated. The conjugates of the present invention also exhibit an extended half-life in vivo compared to the corresponding unconjugated cytokine. The present invention also provides kits comprising such conjugates and/or compositions, and methods of use of such conjugates and compositions in a variety of diagnostic, prophylactic, therapeutic and bioprocessing applications, including treatment of multiple sclerosis.
INTRODUCTION: Lung cancer is the primary cause of cancer-related deaths worldwide, with high rates of morbidity and mortality. The most effective treatment for early stage (I-II) non-small cell lung cancer (NSCLC) is surgical resection. However, the extent of mediastinal lymph nodes removal required and the impact of their removal remains controversial. This systematic review and meta-analysis aimed to evaluate the postoperative complications in patients with stage I-II NSCLC who received mediastinal lymph node dissection (MLND) or mediastinal lymph node sampling (MLNS).
METHODS AND ANALYSIS: According to the predefined inclusion criteria, we will conduct a comprehensive search for randomized controlled trials (RCTs) and observational studies examining the postoperative complications of MLND compared to MLNS in patients with stage I-II NSCLC. The search will be performed across multiple databases including PubMed, Embase, the Cochrane Library, CNKI, WanFang, Sinomed, VIP, Duxiu, and Web of Science from inception to February 2024. Additionally, relevant literature references will be retrieved and hand searching of pertinent journals will be conducted. Screening, data extraction, and quality assessment will be performed by two independent reviewers. Review Manager 5.4 will be applied in analyzing and synthesizing. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) will be used to assess the quality of evidence for the whole RCTs and used Newcastle-Ottawa scale to assess the methodologic quality of observational studies.
ETHICS AND DISSEMINATION: This study did not include personal information. Ethical approval was not required for this study. This study is based on a secondary analysis of the literature, so ethical review approval is not required. The final report will be published in a peer-reviewed journal.
CONCLUSION: This systematic review will contribute to compare the safety and survival benefits of these two surgical techniques for the treatment of early stage NSCLC, to further guide the selection of surgical approaches.
TRIAL REGISTRATION: The protocol of the systematic review has been registered on Open Science Framework, with a registration number of DOI https://doi.org/10.17605/OSF.IO/N2Y5D.
Disclosed herein are methods demonstrating that growth-hormone releasing hormone (GHRH) directly activates cellular reparative mechanisms within the injured heart, in a GH/IGF-I independent fashion. Following experimental myocardial infarction (MI), rats were randomly assigned to receive, during a 4 week period, either placebo (n=14), rat recombinant GH (rrGH, n=8) or JI-38 (n=8; 50 μg/Kg/day), a potent GHRH-agonist. JI-38 did not elevate serum levels of GH or IGF-I, but markedly attenuated the degree of cardiac functional decline and remodeling after injury. In contrast, GH administration markedly elevated body weight, heart weight, circulating GH and IGF-I, but did not offset the decline in cardiac structure and function. Whereas, both JI-38 and GH augmented levels of cardiac precursor cell proliferation, only JI-38 increased anti-apoptotic gene expression. Collectively, these findings demonstrate that within the heart, GHRH-agonists can activate cardiac repair following MI.
The method is used in the pharmaceutical industry. The lovastatin produced has higher purity and yield, and is stable during storage. It is extracted by filtration from the cultural liquor at pH values from 9.5 to 13.0 and is sedimented from the filtrate included in solid mass at pH 2-4 in the presence of inert filler, antioxidant and 0.1-3% organic solvent which does not mix in water. It is extracted and lactonized in chlorine-containing solvent medium. The latter is concentrated and the residue is dissolved in a mixture of solvents of different polarity. In cooling from -10 to -30 deg.C the lovastatin crystallizes, is isolated and is dried. 4 claims
AIM: In terms of early-term mortality, there may be variability in terms of factors belonging to age groups. While some risk factors apply to all patients undergoing colorectal cancer surgery, some factors may come to the fore in terms of age. There have been very few studies on factors that increase the risk of early-term mortality, especially for geriatric patients. It was aimed to compare factors influencing prognosis and mortality within the first 30 postoperative days between geriatric patients and those <65 years of age, and to identify factors that increase the risk of anastomotic leakage and early-term mortality, particularly in geriatric patients.
METHODS: Clinical, laboratory, and pathology findings from 341 patients (186 geriatric) who underwent surgery for colorectal cancer between January 2016 and December 2019 were collected and analyzed. In terms of categorical variables, comparisons between groups were made with Pearson's Chi Square test and Fisher's Exact Test. Risk coefficients of variables in terms of anastomotic leakage and early-term mortality were determined by logistic regression analysis. The results were evaluated within the 95% Confidence interval, and p < 0.05 values were considered significant.
RESULTS: Anastomotic leakage was detected in 7% of patients, and 6.2% of the patients died within the first 30 postoperative days. The 30-day postoperative mortality rate was significantly higher in geriatric patients with hypertension (p = 0.003), those undergoing emergency surgery (p = 0.007), those with stage 4 tumors (p < 0.001), those with ostomy-related complications (p = 0.042), those who developed intraabdominal abscess or peritonitis (p < 0.001), those with respiratory failure (p = 0.009), and those with perforation (p = 0.001). In patients <65 years of age, groups stratified by these variables did not differ significantly in terms of early-term mortality rate (p > 0.05 for each).
CONCLUSIONS: These findings show that lack of bowel preparation and development of intraabdominal abscess/peritonitis significantly increase early-term mortality rates in both <65 and geriatric patients. Additionally, hypertension, emergency surgery, advanced tumor stage, development of ostomy-related complications, respiratory failure, and perforation significantly increase early-term mortality solely in geriatric patients.
Deep NMB, defined by (0 twitch count in the TOF, 1±2 twitch responses in the post-tetanic count. The device which will be used is neuromuscular transmission monitor (NMT) to test the depth of muscle relaxation after giving rocuronium which is a muscle relaxant during general anesthesia.
Lung transplantation has emerged as a viable therapeutic option in the care of patients with advanced pulmonary parenchymal and pulmonary vascular disease. Currently, over 10,000 patients have received lung transplantation with approximately 1200 transplant operations performed worldwide each year. Short term survival after lung transplantation has continued to improve since the widespread application of this procedure and one-year survival at most centers now approaches 80%. Unfortunately, long-term outcomes after lung transplantation are disappointing with five-year survival below 50%. Most posttransplant deaths are due directly or indirectly to the development of chronic allograft rejection, which affects approximately 50% of all five-year survivors. Acute rejection is the major risk factor for the development of chronic rejection. Chronic lung rejection leads to a condition of irreversible fibrosis and obliteration of the small to medium size bronchioles known as obliterative bronchiolitis (OB). Very little is known about the pathogenic mechanisms that lead to the development of OB. Furthermore, it is unclear why acute rejection leads to the development of chronic rejection in some but not all patients. In order to better understand the mechanisms of OB we propose a series of experiments designed to evaluate differences in airway gene expression in a series of lung transplant recipients with and without acute rejection.
The invention discloses an anti-myostatin single-chain antibody, and a coding gene, an expression vector, a recombinant transformant as well as application. The anti-myostatin single-chain antibody comprises a heavy chain variable region, a light chain variable region, and a connecting peptide. The amino acid sequence of the heavy chain variable region is shown as SEQ ID NO.1, the amino acid sequence of the light chain variable region is shown as SEQ ID NO.2, and the amino acid sequence of the connecting peptide is shown as SEQ ID NO.3. The invention also provides the coding gene, the expression vector and the recombinant transformant of the anti-myostatin single-chain antibody. The invention also provides application of the anti-myostatin single-chain antibody in preparation of drugs treating muscle atrophy or animal weight increment drugs. The anti-myostatin single-chain antibody provided in the invention can achieve large-scale expression production in Escherichia coli at a low cost. And the anti-myostatin single-chain antibody has the advantages of small molecular weight, strong tissue penetration power, low immunogenicity, and strong antibody affinity.
Epithelial ovarian cancers (EOC) associated with germline or somatic BRCA pathogenetic variants have a significantly higher rate of TP53aberrations. The majority of TP53 mutations are detectable by immunohistochemistry and several studies demonstrated that an abnormal p53 pattern characterized high-grade EOCs. An abnormal p53 immunohistochemical staining in fallopian tube (serous tubal intraepithelial carcinoma (STIC) and "p53 signature" is considered as a precancerous lesion of high-grade EOCs and it is often found in fallopian tube tissues of BRCA germline mutated patients suggesting that STIC is an early lesion and the TP53 mutation is an early driver event of BRCA mutated high-grade EOCs. No relevant data are present in literature about the involvement of p53 abnormal pattern in EOC carcinogenesis of patients negative for germline BRCA variants. We describe TP53 mutation results in relationship to the immunohistochemical pattern of p53 expression in a series of EOCs negative for BRCA1 and BRCA2 germline mutations. In addition, we also investigated STIC presence and "p53 signature" in fallopian tube sampling of these EOCs. Our results demonstrate that TP53 alterations are frequent and early events in sporadic EOCs including also low-grade carcinomas. Also in this series, STIC is associated with an abnormal p53 pattern in fallopian tubes of high-grade EOCs. In summary, TP53 aberrations are the most frequent and early molecular events in EOC carcinogenesis independently from BRCA mutation status.
Patients randomized to this arm received an NVA237 44 μg capsule in the morning and a placebo capsule in the evening for 26 weeks. All participants received salbutamol as rescue medicine.
Non-human mammalian cell lines which express the major human rhinovirus receptor protein. The cell lines are prepared by gene transfection of human DNA, such as HeLa cell DNA, into non-human mammalian cells, such as mouse cells. Primary transfectants can be transfected into further non-human mammalian cells to provide secondary transfectants. Cloning of secondary transfectants yields cell lines that exhibit enhanced expression of the surface receptor protein. The transfectant cell lines provide a means for cloning the major human rhinovirus receptor protein gene and immunogens for producing antibodies, particularly monoclonal antibodies, against the receptor protein. A general method for screening drug candidates for their ability to block ligand binding to a human cell surface receptor protein is also provided.
During the 12 weeks that the Immediate Intervention (II) group participates in the PCS intervention, the Delayed Intervention (DI) group waits (there is no control intervention) and serves as a control arm comparison for the II group during this time. After the 12 weeks, the DI group will undergo a second pre-intervention assessment to document any change in baseline measures that may have occurred in those 12 weeks. No significant changes are expected. The DI group then begins the same exercise intervention (75-minute group class, twice weekly for 12 weeks; home practice of exercises recommended but not required) that the II group underwent, given by the same instructors. Post-intervention clinical assessments, 12-week follow-up period, and final clinical assessments after the follow-up period as described for the II group. After the trial, pooled data from both groups will provide results on the overall changes in outcome measures post- versus pre-intervention.
OBJECTIVE: This study aimed to explore the correlation between microbiota dysbiosis and hypothyroidism in early pregnancy by 16S rRNA amplicon sequencing combined with metagenomic sequencing.
METHODS: Sixty pregnant women (30 with hypothyroidism and 30 normal controls) were recruited for 16S rRNA amplicon sequencing, and 6 patients from each group were randomly selected for metagenomic sequencing to assess the gut microbiome profile.
RESULTS: The 16S rRNA results showed that beta-diversity in the hypothyroidism group was decreased. The relative abundances of the Prevotella and Paraprevotella genera increased in the hypothyroidism group, and Blautia predominated in the controls. The metagenomics results revealed that Prevotella_stercorea_CAG_629, Prevotella_hominis, Prevotella_sp_AM34_19LB, etc. were enriched in the hypothyroidism group at the species level. Functional analysis revealed that the pyridoxal 5'-phosphate synthase pdxT subunit module was decreased, and the short-chain fatty acid (SCFA) transporter and phospholipase/carboxylesterase modules were strongly enriched in the hypothyroidism group. Hypothyroidism patients had increased C-reactive protein (CRP), interleukin-2 (IL-2), IL-4, IL-10, and tumor necrosis factor (TNF)-α levels. The pyridoxal 5'-phosphate synthase pdxT subunit, the SCFA transporter, and the phospholipase/carboxylesterase module were associated with different Prevotella species.
CONCLUSION: In early pregnancy, women with hypothyroidism exhibit microbiota dysbiosis, and Prevotella may affect the metabolism of glutamate, SCFA, and phospholipases, which could be involved in the development of hypothyroidism during pregnancy.